Company: NCEL
Filing Date: 2025-03-03
Form Type: F-4/A
Source: 0001213900-25-018981
Chunk: 393

Company: NewcelX Ltd.
Filing Date: 2025-03-03
Form: F-4/A
Chunk 393
---
 communications should be sent in care of NLS at , and its telephone number is . Each communication will be forwarded, depending on the subject matter, to the Board, the appropriate committee chairperson or all non -managementdirectors. LEGAL MATTERS Certain legal matters concerning this proxy statement/prospectus will be passed upon for us by Sullivan & Worcester LLP, New York, New York. Certain legal matters with respect to Swiss law will be passed upon for us by Baker McKenzie Switzerland AG, Zurich, Switzerland. Certain legal matters with respect to Kadimastem and Israeli law will be passed upon for us by Pearl Cohen Zedek Latzer Baratz LLP. EXPERTS The financial statements incorporated in this proxy statement/prospectus by reference to the Annual Report on Form 20 -Ffor the year ended December 31, 2023 have been so incorporated in reliance on the report (which contains an explanatory paragraph relating to NLS’s ability to continue as a going concern as described in Note 1 to the financial statements) of PricewaterhouseCoopers AG, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting. The financial statements of Kadimastem Ltd. included in NLS Pharmaceutics Ltd.’s Form 6 -Kfiled with the SEC on November 12, 2024, for the year ended December 31, 2023, have been audited by Kost Forer Gabbay & Kasierer, a Member of EY Global, independent registered public accounting firm, as set forth in their report thereon (which contains an explanatory paragraph describing conditions that raise substantial doubt about Kadimastem Ltd.’s ability to continue as a going concern as described in Note 1B to the financial statements) and incorporated herein by reference. Such financial statements are incorporated herein by reference in reliance upon such report given on the authority of such firm as experts in accounting and auditing. 236 DELIVERY OF DOCUMENTS TO SHAREHOLDERS Pursuant to the rules of the SEC, NLS and services that it employs to deliver communications to its shareholders are permitted to deliver to two or more shareholders sharing the same address a single copy of each of NLS’s annual report to shareholders and NLS’s proxy statement. Upon written or oral request, NLS will deliver a separate copy of the annual report to any shareholder and/or proxy statement to any shareholder at a shared address to which a single copy of each document was delivered and who wishes to receive